SG10202002591QA - Treatment of coagulation disease by administration of recombinant vwf - Google Patents
Treatment of coagulation disease by administration of recombinant vwfInfo
- Publication number
- SG10202002591QA SG10202002591QA SG10202002591QA SG10202002591QA SG10202002591QA SG 10202002591Q A SG10202002591Q A SG 10202002591QA SG 10202002591Q A SG10202002591Q A SG 10202002591QA SG 10202002591Q A SG10202002591Q A SG 10202002591QA SG 10202002591Q A SG10202002591Q A SG 10202002591QA
- Authority
- SG
- Singapore
- Prior art keywords
- administration
- treatment
- recombinant vwf
- coagulation disease
- coagulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495884P | 2011-06-10 | 2011-06-10 | |
| US201161511901P | 2011-07-26 | 2011-07-26 | |
| US201161523790P | 2011-08-15 | 2011-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202002591QA true SG10202002591QA (en) | 2020-05-28 |
Family
ID=46321496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201604684WA SG10201604684WA (en) | 2011-06-10 | 2012-06-11 | Treatment of coagulation disease by administration of recombinant vwf |
| SG10202002591QA SG10202002591QA (en) | 2011-06-10 | 2012-06-11 | Treatment of coagulation disease by administration of recombinant vwf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201604684WA SG10201604684WA (en) | 2011-06-10 | 2012-06-11 | Treatment of coagulation disease by administration of recombinant vwf |
Country Status (24)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012267458A1 (en) * | 2011-06-10 | 2014-01-09 | Baxalta GmbH | Treatment of coagulation disease by administration of recombinant VWF |
| CN102776260B (zh) * | 2012-07-26 | 2015-04-29 | 上海泰龙生物医药科技有限公司 | 一种高效表达重组人凝血八因子的方法 |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| EP4343774A3 (en) | 2016-04-15 | 2024-06-05 | Takeda Pharmaceutical Company Limited | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| WO2019010497A1 (en) | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION |
| FI3648787T3 (fi) | 2017-07-07 | 2025-01-20 | Takeda Pharmaceuticals Co | Elektiiviseen leikkaustoimenpiteeseen osallistuvien vaikeaa von willebrandin tautia sairastavien potilaiden hoito antamalla rekombinanttia vwf:ää |
| CA3089211A1 (en) | 2018-02-06 | 2019-08-15 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
| WO2019183290A1 (en) * | 2018-03-21 | 2019-09-26 | Baxalta Incorporated | Separation of vwf and vwf propeptide by chromatographic methods |
| BR112021015068A2 (pt) | 2019-02-01 | 2021-10-05 | Takeda Pharmaceutical Company Limited | Métodos de tratamento profilático usando vwf recombinante (rvwf) |
| CN114929260A (zh) * | 2019-09-11 | 2022-08-19 | 武田药品工业株式会社 | 与冯维勒布兰德因子和补体c1q的复合物相关的治疗方法 |
| WO2021158777A1 (en) | 2020-02-04 | 2021-08-12 | Baxalta Incorporated | Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf |
| AU2021387981A1 (en) * | 2020-11-24 | 2023-07-06 | Band Therapeutics, Llc | Compositions and methods for treatment of bleeding disorders |
| WO2024124136A1 (en) * | 2022-12-09 | 2024-06-13 | Vega Therapeutics, Inc. | Von willebrand disease animal models |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4638028A (en) | 1985-04-08 | 1987-01-20 | Goodyear Tire & Rubber Company | Rubber polymerases and methods for their production and use |
| WO1986006096A1 (en) | 1985-04-11 | 1986-10-23 | The Children's Medical Center Corporation | Von willebrand factor |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT406373B (de) * | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| US6864403B1 (en) | 1998-10-15 | 2005-03-08 | E. I. Du Pont De Nemours And Company | Plant protein disulfide isomerases |
| US20040014657A1 (en) * | 2001-11-05 | 2004-01-22 | Jan Ohrstrom | Use of blood coagulation factor XIII for treating haemophilia A |
| WO2005012354A1 (en) | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| US7884075B2 (en) * | 2004-12-27 | 2011-02-08 | Baxter International Inc. | Polymer-factor VIII-von Willebrand factor-conjugates |
| CN102643777A (zh) | 2006-01-04 | 2012-08-22 | 巴克斯特国际公司 | 无寡肽的细胞培养基 |
| AU2008261261B2 (en) * | 2007-06-13 | 2013-06-27 | Csl Behring Gmbh | Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
| WO2009062100A1 (en) | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| JP2009127455A (ja) | 2007-11-20 | 2009-06-11 | Bando Kiko Co Ltd | 往復動エンジン |
| EP2244814B1 (en) * | 2007-12-28 | 2021-06-02 | Takeda Pharmaceutical Company Limited | Recombinant vwf formulations |
| ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| ES2409032T3 (es) * | 2008-10-21 | 2013-06-24 | Baxter International Inc. | Formulaciones liofilizadas de vwf recombinante |
| WO2011017414A2 (en) * | 2009-08-04 | 2011-02-10 | Baxter International Inc. | Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a |
| NZ605403A (en) | 2010-07-08 | 2014-10-31 | Baxter Healthcare Sa | Method of producing recombinant adamts13 in cell culture |
| US20120006800A1 (en) | 2010-07-09 | 2012-01-12 | Illinois Tool Works Inc. | Weld bead feature communication systems and devices |
| AU2012267458A1 (en) * | 2011-06-10 | 2014-01-09 | Baxalta GmbH | Treatment of coagulation disease by administration of recombinant VWF |
-
2012
- 2012-06-11 AU AU2012267458A patent/AU2012267458A1/en not_active Abandoned
- 2012-06-11 KR KR1020207020667A patent/KR102319868B1/ko active Active
- 2012-06-11 SG SG10201604684WA patent/SG10201604684WA/en unknown
- 2012-06-11 EP EP20216368.9A patent/EP3858375B1/en active Active
- 2012-06-11 JP JP2014514934A patent/JP6347468B2/ja active Active
- 2012-06-11 TR TR2018/08823T patent/TR201808823T4/tr unknown
- 2012-06-11 KR KR1020197010327A patent/KR20190041032A/ko not_active Ceased
- 2012-06-11 PT PT202163689T patent/PT3858375T/pt unknown
- 2012-06-11 PL PL18173179T patent/PL3412305T3/pl unknown
- 2012-06-11 ES ES12728919.7T patent/ES2682249T3/es active Active
- 2012-06-11 CN CN201810079423.5A patent/CN108210889A/zh active Pending
- 2012-06-11 US US13/493,926 patent/US9272021B2/en active Active
- 2012-06-11 PL PL20216368.9T patent/PL3858375T3/pl unknown
- 2012-06-11 KR KR1020147000709A patent/KR101969515B1/ko active Active
- 2012-06-11 DK DK20216368.9T patent/DK3858375T3/da active
- 2012-06-11 SG SG10202002591QA patent/SG10202002591QA/en unknown
- 2012-06-11 PT PT181731795T patent/PT3412305T/pt unknown
- 2012-06-11 ES ES20216368T patent/ES2976169T3/es active Active
- 2012-06-11 CA CA2838845A patent/CA2838845C/en active Active
- 2012-06-11 WO PCT/US2012/041957 patent/WO2012171031A1/en active Application Filing
- 2012-06-11 EP EP12728919.7A patent/EP2717905B1/en active Active
- 2012-06-11 AR ARP120102073A patent/AR086904A1/es not_active Application Discontinuation
- 2012-06-11 CN CN201611071108.5A patent/CN107412743B/zh active Active
- 2012-06-11 FI FIEP20216368.9T patent/FI3858375T3/fi active
- 2012-06-11 MX MX2013014543A patent/MX350582B/es active IP Right Grant
- 2012-06-11 RU RU2014100107A patent/RU2628537C2/ru active
- 2012-06-11 ES ES18173179T patent/ES2860450T3/es active Active
- 2012-06-11 DK DK12728919.7T patent/DK2717905T3/en active
- 2012-06-11 LT LTEP12728919.7T patent/LT2717905T/lt unknown
- 2012-06-11 BR BR112013031795A patent/BR112013031795A2/pt not_active Application Discontinuation
- 2012-06-11 DK DK18173179.5T patent/DK3412305T3/da active
- 2012-06-11 EP EP18173179.5A patent/EP3412305B1/en active Active
- 2012-06-11 PT PT127289197T patent/PT2717905T/pt unknown
- 2012-06-11 PL PL12728919T patent/PL2717905T3/pl unknown
- 2012-06-11 HR HRP20180962TT patent/HRP20180962T1/hr unknown
- 2012-06-11 CN CN201280038870.7A patent/CN103732244A/zh active Pending
- 2012-06-11 SI SI201231321T patent/SI2717905T1/sl unknown
- 2012-06-11 RU RU2017102679A patent/RU2680402C2/ru active
- 2012-06-11 HU HUE12728919A patent/HUE039317T2/hu unknown
-
2013
- 2013-12-10 MX MX2020000083A patent/MX2020000083A/es unknown
-
2015
- 2015-12-30 US US14/985,212 patent/US20160184403A1/en not_active Abandoned
-
2016
- 2016-04-13 AU AU2016202299A patent/AU2016202299B2/en active Active
- 2016-07-12 JP JP2016137381A patent/JP6527114B2/ja active Active
-
2017
- 2017-07-20 AU AU2017206235A patent/AU2017206235B2/en active Active
-
2018
- 2018-12-27 HK HK18116648.2A patent/HK1257436A1/zh unknown
- 2018-12-28 JP JP2018246475A patent/JP2019048892A/ja active Pending
-
2020
- 2020-01-02 AU AU2020200026A patent/AU2020200026A1/en not_active Abandoned
-
2022
- 2022-03-04 AU AU2022201518A patent/AU2022201518B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201604684WA (en) | Treatment of coagulation disease by administration of recombinant vwf | |
| ZA201505849B (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
| IL239488B (en) | A gpc3-targeted medicinal agent administered to a patient who responds to treatment with a gpc3-targeted medicinal agent | |
| ZA201308417B (en) | Tissue healing | |
| PT2779973T (pt) | Interface de paciente com aplanação variável | |
| ZA201309557B (en) | Methods of treatment for retinal diseases | |
| IL229591A0 (en) | Addition of medicine | |
| ZA201308176B (en) | Therapeutic treatment | |
| ZA201306556B (en) | Variants of human gdnf | |
| LT2780003T (lt) | Antinksčių nepakankamumo gydymas | |
| GB201101770D0 (en) | Treatment of inflammatory respiratory disease | |
| GB201204645D0 (en) | Treatment of disease | |
| GB201201778D0 (en) | Treatment of inflammatory respiratory disease | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds |